文献速递临床试验与 GCP

比伐卢定与肝素单药治疗在心肌梗死中的比较

Bivalirudin versus Heparin Monotherapy in Myocardial Infarction.
PubMed 文献 · N Engl J Med · 2017-08-27

这项多中心、随机、注册基础的开放标签试验纳入6006例接受经皮冠状动脉介入治疗(PCI)的ST段抬高型或非ST段抬高型心肌梗死患者,随机接受比伐卢定或肝素。180天随访时,比伐卢定组主要终点事件发生率为12.3%,肝素组为12.8%(HR 0.96;95%CI 0.83-1.10;P=0.54),差异无统计学意义。

要点

  • 在计划不使用糖蛋白IIb/IIIa抑制剂且以桡动脉入路为主的PCI患者中,比伐卢定与肝素单药治疗的180天主要终点事件无显著差异。
  • 比伐卢定组主要终点事件12.3% vs 肝素组12.8%(HR 0.96;95%CI 0.83-1.10;P=0.54)。
  • 心肌梗死、大出血、明确支架血栓和死亡等次要终点在两组间均无显著差异。

核心结论

  • 在接受PCI的心肌梗死患者中,比伐卢定组的主要终点(全因死亡、心肌梗死或大出血的复合终点)发生率未低于肝素单药治疗组。

研究设计与样本

  • 多中心、随机、注册基础的开放标签临床试验,纳入6006例接受PCI并接受强效P2Y12抑制剂(替格瑞洛、普拉格雷或坎格瑞洛)治疗且计划不使用糖蛋白IIb/IIIa抑制剂的心肌梗死患者(3005例STEMI和3001例NSTEMI)。
  • 患者随机接受PCI期间比伐卢定或肝素治疗,PCI以桡动脉入路为主。
  • 主要终点为180天随访期间全因死亡、心肌梗死或大出血的复合终点。

主要发现

  • 180天时,比伐卢定组主要终点事件发生率为12.3%(369/3004),肝素组为12.8%(383/3002)(HR 0.96;95%CI 0.83-1.10;P=0.54)。
  • 心肌梗死发生率比伐卢定组2.0% vs 肝素组2.4%(HR 0.84;95%CI 0.60-1.19;P=0.33)。
  • 大出血发生率比伐卢定组8.6% vs 肝素组8.6%(HR 1.00;95%CI 0.84-1.19;P=0.98)。
  • 明确支架血栓发生率比伐卢定组0.4% vs 肝素组0.7%(HR 0.54;95%CI 0.27-1.10;P=0.09)。
  • 死亡发生率比伐卢定组2.9% vs 肝素组2.8%(HR 1.05;95%CI 0.78-1.41;P=0.76)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The comparative efficacy of various anticoagulation strategies has not been clearly established in patients with acute myocardial infarction who are undergoing percutaneous coronary intervention (PCI) according to current practice, which includes the use of radial-artery access for PCI and administration of potent P2Y12 inhibitors without the planned use of glycoprotein IIb/IIIa inhibitors. METHODS: In this multicenter, randomized, registry-based, open-label clinical trial, we enrolled patients with either ST-segment elevation myocardial infarction (STEMI) or non-STEMI (NSTEMI) who were undergoing PCI and receiving treatment with a potent P2Y12 inhibitor (ticagrelor, prasugrel, or cangrelor) without the planned use of glycoprotein IIb/IIIa inhibitors. The patients were randomly assigned to receive bivalirudin or heparin during PCI, which was performed predominantly with the use of radial-artery access. The primary end point was a composite of death from any cause, myocardial infarction, or major bleeding during 180 days of follow-up. RESULTS: A total of 6006 patients (3005 with STEMI and 3001 with NSTEMI) were enrolled in the trial. At 180 days, a primary end-point event had occurred in 12.3% of the patients (369 of 3004) in the bivalirudin group and in 12.8% (383 of 3002) in the heparin group (hazard ratio, 0.96; 95% confidence interval [CI], 0.83 to 1.10; P=0.54). The results were consistent between patients with STEMI and those with NSTEMI and across other major subgroups. Myocardial infarction occurred in 2.0% of the patients in the bivalirudin group and in 2.4% in the heparin group (hazard ratio, 0.84; 95% CI, 0.60 to 1.19; P=0.33), major bleeding in 8.6% and 8.6%, respectively (hazard ratio, 1.00; 95% CI, 0.84 to 1.19; P=0.98), definite stent thrombosis in 0.4% and 0.7%, respectively (hazard ratio, 0.54; 95% CI, 0.27 to 1.10; P=0.09), and death in 2.9% and 2.8%, respectively (hazard ratio, 1.05; 95% CI, 0.78 to 1.41; P=0.76). CONCLUSIONS: Among patients undergoing PCI for myocardial infarction, the rate of the composite of death from any cause, myocardial infarction, or major bleeding was not lower among those who received bivalirudin than among those who received heparin monotherapy. (Funded by the Swedish Heart-Lung Foundation and others; VALIDATE-SWEDEHEART ClinicalTrialsRegister.eu number, 2012-005260-10 ; ClinicalTrials.gov number, NCT02311231 .).

来源:N Engl J Med,查看原文。版权归原作者所有。

引用

  1. Erlinge D, Omerovic E, Fröbert O, et al. Bivalirudin versus Heparin Monotherapy in Myocardial Infarction. N Engl J Med. 2017. PMID: 28844201. doi:10.1056/NEJMoa1706443

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。